⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 24, 2024Translational OncologyOpen Access

Improved survival of patients with stage III small-cell lung cancer with primary resection: A SEER-based analysis

Jianlong Jia Lilith Trassl Fanli Kong Benteng Deng Ruonan Liu Zhengwu Sun Xiaoyan Lan Ali Önder Yildirim Georgios T. Stathopoulos Isis E. Fernandez Andrea C. Schamberger

View Full Paper

Ask AI

Bookmark

Share

Abstract

Small cell lung cancer (SCLC) is mostly diagnosed in stage III-IV patients and associated with poor prognosis. To date, surgery is no gold-standard treatment for any SCLC stage and evidence is lacking whether it is beneficial. Here we investigate the impact of surgery, with special attention to stage III SCLC patients, sub-stages and treatment combinations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jia et al. (2024) studied this question.

synapsesocial.com/papers/68e5b130b6db64358754a3cc https://doi.org/10.1016/j.tranon.2024.102070

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Closing the RCT Gap—A Large Meta-Analysis on the Role of Surgery in Stage I–III Small Cell Lung Cancer Patients2024
2Different treatment modalities on the prognosis of patients with stage I–IIIa small cell lung cancer: a population based study2024 · 2 citations
3Effect of surgery on survival of patients with small-cell lung cancer undiagnosed before resection2024
4Debate: why surgery should remain central in the management of locally advanced (Stage III) non-small-cell lung cancerHuman Clinical Trial · 2026
5CD3, CD8, IFN-γ, tumor and stroma inflammatory cells as prognostic indicators for surgically resected SCLC: evidences from a 10-year retrospective study and immunohistochemical analysis2024 · 3 citations